News

A survey explores how physicians perceive their role in the healthcare system, and the findings aren’t good.

A Physicians Foundation survey gives healthcare executives behind the scenes insight into the physician-patient relationship.

FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.

With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.

CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.

A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.

CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.

Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?

External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.

One expert says incentive programs to motivate physicians miss the mark. Here’s what he recommends instead.

As the healthcare system shifts from a focus on employee-based plans to consumer-based plans, insurers have to find new ways to engage and motivate members.

Providers are coming up short when it comes to HEDIS measures related to substance abuse. Here’s how one health plan is changing that.

The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.

Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.

Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.

Avalere Health analysis has intriguing results about beneficiaries enrolled in diabetes-focused chronic condition special needs plans.

FDA Commissioner Scott Gottlieb, MD, said that the United States is likely to see shortages on certain drugs because after Hurricanes Irma and Maria knocked out power to the islands.

Why researchers say the industry is “a long way off” from robust electronic patient data sharing.

Trump takes two steps to dissolve the ACA. Find out what the experts think about these two important actions.

Here’s a quick guide to the meaning behind Trump’s executive order and decision to stop cost-sharing reduction payments.

Here’s how to take consumer-centricity more seriously as expectations increase.

The FDA pushes back on new painkiller’s abuse-deterrent claims. Here’s why this is important to the opioid epidemic.

As the industry moves to a value-based care model, here’s how one North Texas partnership is reinventing healthcare.

Acute myeloid leukemia experts share promising new developments on the oncology horizon.

A new study uses population health analytics to identify potential opioid abuse, and the study findings are troubling.

Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.

Recent study findings reveal which patients are more likely to be readmitted for COPD problems, and which readmission reduction strategies might work best.

Consider these five opportunities to help curb one of the biggest public health issues of the year.